ESR1 and breast carcinoma: In breast cancer patients treated with aromatase inhibitors, the screening of CYP19A1, CYP17A1, CYP27B1, TCLA1, RANK/RANKL/OPG, and ESR1/ESR2 variants may be of some utility to optimize positive effects and reduce ADRs [140].